Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atumelnant Drug-Drug Interaction Study in Healthy Participants
NCT07570082Phase 1Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- May 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of atumelnant in Cushing's disease (CD) and congenital adrenal hyperplasia (CAH) (2 cohorts), sponsored by Crinetics Pharmaceuticals. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at Day 34, Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity at Day 34 and 1 more. Started May 2026; status: completed.
02
Drugs
atumelnant
03
Conditions
Cushing's disease (CD)congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT07570082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570082.